Skip to main content
. 2018 Aug 31;56(4):212–218. doi: 10.5114/reum.2018.77972

Table III.

Difference in HAQ-DI, QALY, and improvement of DAS28 and direct costs according to treatment regimen per patient

  Infliximab Etanercept Adalimumab
Decrease of HAQ-DI 0.45 0.21 0.18
QALY 1.71 0.74 0.60
Improvement of DAS28 3.30 3.51 3.70
Average medical cost per patient 64,263.61 72,866.19 81,494.04

DAS28 – Disease Activity Score 28; HAQ-DI – Health Assessment Questionnaire Disability Index; QALY – quality-adjusted life years